EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Patterns of psychotropic medication prescribing and potential drug-hormone interactions among transgender and gender-diverse adults within 2 years of hormone therapy

Alin Kalayjian, Kaeleb Laszlo, Molly Fassler, Zachary Schonrock, Kikka E Delarose, Andrew M Ly, Clayton D English, Lauren R Cirrincione

Journal of the American Pharmacists Association · 2024

DOI: 10.1016/j.japh.2023.10.005 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of the American Pharmacists Association, 2024. Verfasst von Alin Kalayjian und 7 weiteren Autor:innen. Hauptthemen laut MEDLINE: Transgender Persons. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIGMS NIH HHS, NCATS NIH HHS, National Institutes of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Transgender and gender-diverse (TGD) people have a high prevalence of psychotropic medication use, yet knowledge about the patient-level psychotropic medication burden is limited. TGD patients may take hormone therapy to meet their gender expression goals. Potential drug-hormone interactions exist between psychotropic medications and hormone therapy, requiring increased knowledge about psychotropic medication use for TGD adults undergoing hormone therapy. OBJECTIVES: The objective of this study was to examine the extent of psychotropic medication polypharmacy in a cohort of TGD adults within 2 years of starting hormone therapy. We also characterized potential drug-hormone interactions and the association with psychotropic polypharmacy. METHODS: Retrospective cross-sectional analysis of patients with ≥1 transgender health-related visit (2007-2017) in the University of Washington Medical System (Seattle, WA). Eligible patients had ≥1 psychotropic medication including antidepressants, antipsychotics, mood stabilizers, and sedative-hypnotics ordered within 2 years of starting hormone therapy (testosterone or estradiol with or without spironolactone, progesterone, finasteride, or dutasteride). We defined psychotropic polypharmacy as ≥2 psychotropic medication orders with overlapping treatment durations for at least 90 days and characterized potential drug-hormone interactions (Lexicomp, Hudson, OH). We descriptively summarized patients with and without polypharmacy (frequencies and percentages) and compared drug-hormone interactions using chi-square or Fishers exact tests (P < 0.05 considered significant). RESULTS: A total of 184 patients had ≥1 psychotropic medication order within 2 years of hormone therapy; 68 patients (37.0%) had psychotropic polypharmacy. The most frequent type of psychotropic polypharmacy was antidepressant+sedative-hypnotic (18 of 68, 26.5%). More patients had a potential drug-hormone interaction among those with psychotropic polypharmacy (23 of 68, 33.8%) versus those without (8 of 116, 6.9%, P < 0.001). CONCLUSION: Among TGD patients on psychotropic medications within 2 years of hormone therapy, one-third had psychotropic polypharmacy. Most polypharmacy types appeared to align with mental health treatment guidelines. The number of patients with a potential drug-hormone interaction was significantly higher among those with polypharmacy. Prospective studies are needed to characterize drug-hormone interactions.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Transgender PersonsAdultHumansRetrospective StudiesCross-Sectional StudiesPsychotropic DrugsAntidepressive AgentsPolypharmacyHypnotics and SedativesHormonesMaleFemale

Substanzen

Psychotropic DrugsAntidepressive AgentsHypnotics and SedativesHormones

Förderung

  • NIGMS NIH HHS
  • NCATS NIH HHS
  • National Institutes of Health
  • National Institute of General Medical Sciences
  • National Center for Advancing Translational Sciences

Zitieren

APA

Kalayjian, A., Laszlo, K., Fassler, M., Schonrock, Z., Delarose, K. E., Ly, A. M., English, C. D., & Cirrincione, L. R. (2024). Patterns of psychotropic medication prescribing and potential drug-hormone interactions among transgender and gender-diverse adults within 2 years of hormone therapy. Journal of the American Pharmacists Association. https://doi.org/10.1016/j.japh.2023.10.005

Vancouver

Kalayjian A, Laszlo K, Fassler M, Schonrock Z, Delarose KE, Ly AM, et al. Patterns of psychotropic medication prescribing and potential drug-hormone interactions among transgender and gender-diverse adults within 2 years of hormone therapy. Journal of the American Pharmacists Association. 2024. doi:10.1016/j.japh.2023.10.005

BibTeX
@article{Kalayjian2024,
  author = {Kalayjian, Alin and Laszlo, Kaeleb and Fassler, Molly and Schonrock, Zachary and Delarose, Kikka E and Ly, Andrew M and English, Clayton D and Cirrincione, Lauren R},
  title = {Patterns of psychotropic medication prescribing and potential drug-hormone interactions among transgender and gender-diverse adults within 2 years of hormone therapy},
  journal = {Journal of the American Pharmacists Association},
  year = {2024},
  doi = {10.1016/j.japh.2023.10.005}
}
Kostenlos starten →